Healthcare
Protalix BioTherapeutics, Inc.(PLX)
Live Price
Offline$2.22
+9.90% today
1Y Change
+64.44%
Window
Jun 23, 2025 β Jun 18, 2026
- Market Cap
- $170.00M
- Revenue Growth
- -1.2%
- EPS Growth
- -308.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 23, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protalix BioTherapeutics, Inc. (PLX) is a Healthcare stock with a market cap of $170.00M and listed on AMEX. The stock last traded around $2.22 and up 64.4% across the available one-year price window (Jun 23, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of -1.2%, EPS growth of -308.2%, a dividend yield of 0.0%. What stands out right now is revenue -1.2%, EPS -308.2%, free cash flow -284.4% with operating margin -10.4% and ROIC -9.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PLX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.2% vs +7.6% peer median
Operating Margin
Below sector median
-10.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.2% and EPS is at -308.2%, with operating margin around -10.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | β | +0.0% | +2.1% | +1.0% |
2026 Mar 18, 2026 | -800.0% | +0.9% | -2.3% | +4.1% |
2025 Nov 13, 2025 | -50.0% | -3.6% | -9.8% | -7.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLX
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
PLX Max Drawdown
-39.68%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLX and SPY.
Company Overview
Protalix BioTherapeutics, Inc.
New York Stock Exchange American
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
- Leadership
- Dror Bashan
- IPO Date
- May 15, 1998
- Employees
- 213
- Street Address
- 2 University Plaza
- Mailing
- Hackensack, NJ, 07601
- Region
- Hackensack, NJ, US
- Reporting Currency
- USD
- Investor Line
- 201 696 9345
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 3.2
- Price/Book
- 3.5
Growth
- Revenue
- -1.2%
- EPS
- -308.2%
- Free Cash Flow
- -284.4%
Profitability
- Gross Margin
- 48.8%
- Operating Margin
- -10.4%
- Net Margin
- -12.5%
- ROE
- -13.5%
- ROIC
- -9.6%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 2.51
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.